Sangamo Announces AAV Capsid Data

Uncategorized

Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

BRISBANE, Calif. --(BUSINESS WIRE)--May 2, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted eight Sangamo abstracts for presentation at the 25 th ASGCT Annual Meeting being held May